Company profile
Dermata Therapeutics, Inc.
NASDAQ:DRMABiotechnology: Pharmaceutical Preparations
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03003104 | phase2 | completed | 2017-01-01 | 2017-08-30 | Dermata Therapeutics | DMT210 Topical Gel in the Treatment of Acne Rosacea |
| NCT02949960 | phase2 | completed | 2016-10-01 | 2017-07-14 | Dermata Therapeutics | DMT210 Topical Gel in the Treatment of Atopic Dermatitis |
| NCT03536637 | phase2 | completed | 2018-05-22 | 2018-12-30 | Dermata Therapeutics | DMT310-001 Topical in the Treatment of Acne Vulgaris |
| NCT04106778 | phase2 | completed | 2019-10-10 | 2020-05-04 | Dermata Therapeutics | DMT310-003 Topical in the Treatment of Acne Vulgaris |
| NCT05108025 | phase2 | unknown | 2021-11-15 | 2022-12-01 | Dermata Therapeutics | DMT310-005 Topical in the Treatment of Acne Rosacea |
FDA applications (0)
No records yet.